^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ZFHX4 (Zinc Finger Homeobox 4)

    i
    Other names: ZFHX4, Zinc Finger Homeobox 4, ZFH4, Zinc Finger Homeobox Protein 4, FLJ20980, Zinc-Finger Homeodomain Protein 4, Zinc Finger Homeodomain Protein 4, Zinc Finger Homeodomain 4, ZFH-4, ZHF4
    Associations

    News

    Trials
    22d
    Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Patients received radiotherapy (50.4 Gy/28 in fractions on 5 days per week), concurrent chemotherapy (paclitaxel 135 mg/m2 d1+ cisplatin 25 mg/m2 d1-3, q3w, 2 cycles), and QL1706 (5 mg/kg q3w for up to 1 year [total of 18 cycles]). QL1706 combined with chemoradiotherapy demonstrated potential antitumor activity and manageable toxicity, supporting further investigation. National Natural Science Foundation of China, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Medical Discipline Construction Project, and Tianjin Key Medical Discipline (Specialty) Construction Project.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • FASLG (Fas ligand) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TMB-H
    |
    cisplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    26d
    Systematic analysis of anoikis-related genes identifies SRPX2-FAK/AKT-IL-6 axis in the progression and peritoneal metastasis of gastric cancer. (PubMed, Front Genet)
    It further reveals that SRPX2 driven anoikis resistance, mediated through the FAK/AKT-IL-6 axis, facilitates peritoneal metastasis. These findings provide new directions for prognostic assessment and therapeutic strategies in gastric cancer.
    Journal
    |
    IL6 (Interleukin 6) • CLEC3B (C-Type Lectin Domain Family 3 Member B) • HTRA1 (HtrA Serine Peptidase 1) • ZFHX4 (Zinc Finger Homeobox 4)
    2ms
    LncRNA ZFHX4-AS1 initiates an oncogenic axis involving a ZFHX4/SOX2 positive feedback loop to accelerate glioma progression. (PubMed, Front Oncol)
    We further establish that this entire axis ultimately converges on the activation of the JAK-STAT pathway. This detailed ZFHX4-AS1/ZFHX4/SOX2/JAK-STAT axis represents a promising set of therapeutic targets for glioma treatment.
    Journal
    |
    SOX2 • ZFHX4 (Zinc Finger Homeobox 4)
    3ms
    Genomic and Demographic Characteristics of Angiosarcoma as Described in the AACR Project GENIE Registry. (PubMed, Cancers (Basel))
    In one of the largest genomic analyses of angiosarcoma to date, we identified recurrent alterations, suggesting potential future therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH2 (Notch 2) • FAT1 (FAT atypical cadherin 1) • FLT4 (Fms-related tyrosine kinase 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • POT1 (Protection of telomeres 1) • MSI2 (Musashi RNA Binding Protein 2) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TP53 mutation • PIK3CA mutation • CDKN2A deletion
    4ms
    HOXB13 interactome in prostate cancer cells: biochemical and functional interactions between the transcription factors HOXB13 and TBX3. (PubMed, Vavilovskii Zhurnal Genet Selektsii)
    Analysis of individual prostate cancer cell lines revealed that knockout of both genes, HOXB13 and TBX3, leads to the death of the same lines: VCaP, LNCaP (clone FGC), PC-3 and 22Rv1. Thus, HOXB13 and TBX3 can be considered together as potential targets for the development of specific inhibitors that suppress prostate cancer cell growth.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ZFHX3 (Zinc Finger Homeobox 3) • HOXB13 (Homeobox B13) • ZFHX4 (Zinc Finger Homeobox 4)
    7ms
    Genetic characteristics of primary bone marrow large B-cell lymphoma. (PubMed, Pathol Res Pract)
    Clinicopathological characteristics, including hemophagocytic lymphohistiocytosis (HLH), hepatosplenomegaly, International Prognostic Index (IPI) score, treatment with chemotherapy plus rituximab, CD5 expression, histopathological patterns, germinal center B-cell-like subtype and follow-up duration, did not differ significantly between the two groups...BTG1 mutation is associated with adverse outcomes, highlighting their potential as prognostic biomarkers or therapeutic targets. These findings advance our understanding of the molecular landscape and prognostic stratification of PBM-LBCL.
    Journal
    |
    KMT2D (Lysine Methyltransferase 2D) • FAT1 (FAT atypical cadherin 1) • CD5 (CD5 Molecule) • APOB (Apolipoprotein B) • BTG1 (BTG Anti-Proliferation Factor 1) • IL16 (Interleukin 16) • ZFHX4 (Zinc Finger Homeobox 4) • BBS9 (Bardet-Biedl Syndrome 9)
    |
    Rituxan (rituximab)
    10ms
    Lactylation-related risk model for prognostication and therapeutic responsiveness in uterine corpus endometrial carcinoma. (PubMed, Discov Oncol)
    This study demonstrates that the lactylation-related risk model plays a crucial role in predicting prognosis and the efficacy of immunotherapy in UCEC, offering valuable insights for personalized treatment approaches.
    Journal • IO biomarker
    |
    ZFHX4 (Zinc Finger Homeobox 4)
    10ms
    Molecular subtyping of endometrial cancer via a simplified one-step NGS classifier, ARID1A and ZFHX4 mutations help further subclassify CNL/MSI-H patients. (PubMed, Diagn Pathol)
    This simplified one-step NGS panel can effectively subgroup EC patients into four prognostically different subtypes. New biomarkers are able to potentially refine the classification of patients with CNL/MSI-H subtypes into groups with distinct clinical outcomes.
    Retrospective data • Journal • Next-generation sequencing • MSi-H Biomarker • MSI-H
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    MSI-H/dMMR • ARID1A mutation
    1year
    Leveraging miRNA-mediated expression profiles to predict prognosis and identify distinct molecular subtypes in ovarian cancer: a multi-cohort study. (PubMed, Int Immunopharmacol)
    Notably, the S3 subtype demonstrated sensitivity to dasatinib but resistance to methotrexate. Finally, we developed a user-friendly Shiny-based website to facilitate the application of our prognostic and subtype classification models (https://jli-bioinfo.shinyapps.io/NCI_online/). This study establishes a critical prognostic marker and proposes a novel molecular classification framework grounded in miRNA-regulated gene expression profiles, advancing our understanding of the non-coding mechanisms driving OV heterogeneity.
    Journal • IO biomarker
    |
    GAS1 (Growth Arrest Specific 1) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    dasatinib • methotrexate
    over1year
    LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients. (PubMed, Clinics (Sao Paulo))
    The authors described the molecular characteristics of CRC. Loss of LRP1B leads to changes in immune cell infiltration and can be used as a therapeutic target for colorectal cancer.
    Journal • Tumor mutational burden • IO biomarker • Immune cell
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • LRP1B (LDL Receptor Related Protein 1B) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • FAT4 (FAT Atypical Cadherin 4) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TP53 mutation • KRAS mutation • APC mutation
    over1year
    Identification and validation of an m7G-related lncRNAs signature for predicting prognosis, immune response and therapy landscapes in ovarian cancer. (PubMed, Front Genet)
    Moreover, the model has certain relevance in the immune cells and functions between high and low risk groups, and simultaneously, the signature has the role of guiding the option of immunotherapy and chemotherapeutic drugs. Altogether, our study established a tight connection between m7G-associated lncRNAs and ovarian cancer, with potential that the prognostic patterns contribute to steering the prognosis of ovarian cancer patients, measuring the efficacy of immunotherapeutic approaches, and detecting effective chemotherapeutic agents.
    Journal • IO biomarker
    |
    KRT7 (Keratin-7) • USP30-AS1 (USP30 Antisense RNA 1) • ZFHX4 (Zinc Finger Homeobox 4)
    over1year
    Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma. (PubMed, Invest New Drugs)
    Seven DNA damage repair pathways were significantly enriched in the ZFHX4-Mut group. ZFHX4 mutation could serve as a predicter for the efficacy of ICIs therapy in NSCLC and melanoma.
    Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ZFHX4 (Zinc Finger Homeobox 4)